Back

Guideline-directed medical therapy patterns in heart failure with reduced ejection fraction: the OPTIMA-HF registry

31 August 2024 (09:00 - 09:40)
Organised by: Logo
Congress Presentation Part of: Angiotensin and angiotensin receptor neprilysin inhibitors in heart failure Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor Stefania Paolillo

University of Naples Federico II, Naples (Italy)

7 More presentations in this session

Presentation thumbnail
Quality of life in patients with heart failure and improved ejection fraction: one-year follow-up with ARNI and SGLT2i
Professor S. Tadic (Novi Sad, RS)
Abstract Slides
Presentation thumbnail
Real world evidence of Sacubitril/Valsartan in octogenarian patients with heart failure. Results From the PARACHUTE-HF Study
Doctor N. Okuda (Kawagoe, JP)
Abstract Slides
Presentation thumbnail
Estimated plasma volume in heart failure with reduced ejection fraction: ACE inhibitors versus angiotensin receptor/neprilysin inhibitor in follow up
Doctor S. Varga (Sisak, HR)
Abstract Slides
Presentation thumbnail
Safety and efficacy of initiation SGLT in heart failure with a reduced left ventricular ejection fraction and chronic kidney disease on top of standard therapy with ARNI or ACE-i
Mrs O. Obertynska (Vinnitsa, UA)
Abstract Slides
Presentation thumbnail
Association of renal circulation at acute phase with decongestion level at discharge in patients admitted for acute decompensated heart failure
Doctor K. Kayama (Nagoya, JP)
Abstract Slides

Access the full session

Session thumbnail
Angiotensin and angiotensin receptor neprilysin inhibitors in heart failure

The Event

Event poster

ESC Congress 2024

31 August 2024 09:00 CET
You may be interested in
thumbnail
Congress Presentation
Elegibility for Sacubitril/Valsartan in italian clinical practice: insights from the OPTIMA-HF registry
thumbnail
Congress Presentation
The implementation of modern guideline-directed medical therapy among hospitalized patients with heart failure with reduced ejection fraction: real-world experience from two tertiary cardiac centers
thumbnail
Congress Presentation
Limitations to guideline directed medical therapy for heart failure with reduced ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources